Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Fineline Cube Apr 13, 2026
Company Deals

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Fineline Cube Apr 13, 2026
Company Deals Drug

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

Fineline Cube Apr 13, 2026
Company Deals

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets

Fineline Cube Apr 13, 2026
Company Deals

Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle

Fineline Cube Apr 13, 2026
Company Drug

FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026

Fineline Cube Apr 13, 2026
Company Deals

Chia Tai Tianqing Secures Exclusive Rights to InventisBio’s D-1553 in China Licensing Deal

Fineline Cube Aug 4, 2023

China-based Chia Tai Tianqing has signed a licensing agreement with compatriot firm InventisBio, securing exclusive...

Company Medical Device

DaVinci Single Port System Launches in Hainan with Successful Surgeries

Fineline Cube Aug 4, 2023

The DaVinci Single Port robot-assisted surgical system technology has been successfully implemented in Boao, Hainan...

Policy / Regulatory

Shanghai’s SMPA Reduces Ceiling Price for Non-Winning Bids in Artificial Joint VBP Tender

Fineline Cube Aug 4, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has issued a notification regarding an artificial joint volume-based...

Company Deals

Kunshan Yiyuan Medical Technology Secures Over RMB 100 Million in Series B Financing

Fineline Cube Aug 4, 2023

Kunshan Yiyuan Medical Technology Co., Ltd (Medical Source), a company in China that specializes in...

Company Deals

HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max

Fineline Cube Aug 4, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm...

Company

Novartis China’s Business Growth Lead Zhu Jiakang Departs for Personal Reasons

Fineline Cube Aug 4, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has seen the departure of Zhu Jiakang, who led...

Company

BeiGene’s Q2 2023 Financial Report Highlights 81.8% YOY Product Revenue Growth

Fineline Cube Aug 3, 2023

China-based biotech company BeiGene (SHA: 688235, HKG: 6160, NASDAQ: BGNE) has released its financial report...

Legal / IP Policy / Regulatory

National Health Commission’s Anti-Corruption Drive Impacts China’s Pharmaceutical Sector

Fineline Cube Aug 3, 2023

An anti-corruption crackdown announced by the National Health Commission (NHC) at the end of July...

Company Medical Device

Our United Corporation’s Linear Accelerator Approved as Innovative Medical Device by NMPA

Fineline Cube Aug 3, 2023

Xi’an-based Our United Corporation has announced that its medical electronic linear accelerator has been approved...

Company Drug

CORXEL Gets CDE Approval for Phase III Presbyopia Trials of LNZ100 and LNZ101

Fineline Cube Aug 3, 2023

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has announced that...

Company Deals

Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Partners with Eyebright Medical Technology

Fineline Cube Aug 3, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has entered...

Company Deals

BeiGene and Bristol-Myers Squibb/Celgene Settle Partnership, Termination Set for 2023

Fineline Cube Aug 3, 2023

BeiGene (NASDAQ: BGNE) has announced a settlement and termination agreement with US firm Bristol-Myers Squibb/Celgene...

Company Medical Device

Suzhou Jiecheng Medical Secures FDA BDD for Transvascular Aortic Valve Treatment

Fineline Cube Aug 3, 2023

Suzhou Jiecheng Medical Technology Co., Ltd has announced that it has obtained Breakthrough Devices Designation...

Company Drug

ABM Therapeutics’ ABM-1310 Earns Orphan Drug Designation for BRAF V600 Mutant Glioblastoma

Fineline Cube Aug 3, 2023

Shanghai-based ABM Therapeutics Inc. has announced that it has received Orphan Drug Designation (ODD) from...

Company Deals

Huaboron Neutron Technology Secures Over RMB 100 Million in Angel Financing for BNCT System

Fineline Cube Aug 3, 2023

Huaboron Neutron Technology (Hangzhou) Co., Ltd (HBNCT) has reportedly secured more than RMB 100 million...

Company Deals

ICE Bioscience Secures Series B+ Financing to Boost Integration Capabilities

Fineline Cube Aug 3, 2023

Beijing-based Contract Research Organization (CRO) ICE Bioscience has reportedly raised close to RMB 100 million...

Company Drug

Sumitomo Pharma and Otsuka’s Ulotaront Fails to Meet Primary Endpoint in Schizophrenia Trials

Fineline Cube Aug 3, 2023

Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) and Otsuka Pharmaceutical Co., Ltd (FRA: OS1) have...

Company

Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials

Fineline Cube Aug 3, 2023

Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) has released its financial results for...

Company Deals

Biogen Inc. to Acquire Reata Pharmaceuticals in $7.3 Billion Deal

Fineline Cube Aug 2, 2023

US-based Biogen Inc., (NASDAQ: BIIB) has announced that it has reached an agreement to fully...

Company

Pfizer Inc. Reports Q2 2023 Revenues, Signals Shift Beyond COVID-19 Products

Fineline Cube Aug 2, 2023

US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the second...

Posts pagination

1 … 476 477 478 … 649

Recent updates

  • Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle
  • Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights
  • FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026
  • GSK’s B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials
  • Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle

Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Company Drug

FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026

Company Drug

GSK’s B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.